BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.

DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye diagnostic solutions, is pleased to announce the ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

SG Americas Securities LLC cut its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) by 28.3% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,518 shares of the company ...